mynth
10/2018100%

Slimfast acquired by Glanbia Nutritionals

UNITED STATES Life Sciences / Nutrition & Dietary Supplements EV $300–700M

Context

Glanbia moved in October 2018 to acquire SlimFast, the weight-management and wellness brand family, from KSF Holdings and HNS Intermediate Corporation, both backed by private equity firm Kainos Capital, for $300–700M. The package also brings nutritional supplement brands Healthy Delights and Nu-Therapy into the fold. Based in Palm Beach Gardens, Florida, SlimFast sells diet shakes, bars, snacks, packaged meals and other supplement foods, distributed mainly through the food, drug, mass and club channel across the US and UK. In 2017 the business generated net sales of $150–250M and adjusted EBITDA before non-recurring costs of $10–30M, though after non-recurring supply chain transition costs it posted a net loss before tax of $12 million; gross assets at the 2017 financial year end stood at $136 million. Glanbia intends to run SlimFast inside its Performance Nutrition segment, alongside Healthy Delights and Nu-Therapy, framing the deal as an adjacency to that portfolio within the $8 billion weight management nutrition market. Kainos had acquired SlimFast from Unilever in 2014, when the business came with no employees or systems; under CEO Chris Tisi the sponsor built a team of more than 60 people in the US and UK, redesigned packaging across the range and relaunched advertising. Final consideration depends on actual working capital at completion, with no other deferred component, and Glanbia will finance the deal from available banking facilities. Closing was anticipated before the end of 2018, subject to customary completion conditions, agreed closing accounts and regulatory approval. Harris Williams and Sawaya Partners advised SlimFast, with Winston & Strawn as legal counsel.

-> Deep-dive in Healthcare & Pharma market trends

Target

SlimFast has built its business around weight management and health & wellness products, sold mainly through food, drug, mass and club retailers in the United States and the United Kingdom. The brand family spans ready-to-drink shakes, ready-to-mix powders, and an Advanced Nutrition line of high-protein, high-fibre, gluten-free meal replacement shakes and smoothies. It also includes supplement brands such as Healthy Delights and Nu-Therapy. The United States remains its largest market, where brand awareness is high. In 2017, the company generated $212 million in net sales. The offer targets everyday consumers looking for convenient formats and snacking options within the weight management space.

Ent. Value

$300–700M

Equity Value

[members only]

Multiples

FREE VIEW

EV / Revenue

1.7x

EV / EBITDA

10x–18x

EV / EBIT

[members only]

Historical Financials (USD)

Year
Rev
EBITDA
EBIT
2017
$150–250M
$10–30M
[members only]
2016
$150–250M
$10–30M
[members only]

Other operations with Slimfast

Other operations with Slimfast
DateAcquirerTargetCountrySector
09/2025HEARTLAND FOOD PRODUCTSSLIMFASTUNITED STATESNutrition & Dietary Supplements

Other operations with Glanbia Nutritionals

Other operations with Glanbia Nutritionals
DateAcquirerTargetCountrySector
04/2024GLANBIA NUTRITIONALSFLAVOR PRODUCERSUNITED STATESIngredients
08/2020GLANBIA NUTRITIONALSFOODAROMCANADAIngredients

Similar deals in Life Sciences

Similar deals in Life Sciences
DateAcquirerTargetCountrySector
12/2018MERCK & CO.ANTELLIQFRANCEAnimal Health
11/2018ARDIANNEOPHARMED GENTILIITALYGenerics / Labs
10/2018ASTORGNEMERAFRANCEMedical Consumables
10/2018BRIDGEPOINTHTL BIOTECHNOLOGYFRANCECDMO
10/2018ARDIANINULA GROUPBELGIUMPharma & Biotech
08/2018DENTRESSANGLEACTEONFRANCEMedical Devices
05/2018PERMIRACORIN GROUPUNITED KINGDOMImplants & Prosthetics
05/2018ZOETISABAXISUNITED STATESDiagnostic Equipment
05/2018NNPARAGON MEDICALUNITED STATESMedical Devices
02/2018CVCTHERAMEXUNITED KINGDOMPharma & Biotech

REFERENCES

Valuation range: EV $300–700M

Revenue range: $150–250M

EBITDA range: $10–30M

EV/Revenue range: 1x - 3x

EV/EBITDA range: 10x - 18x

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Slimfast by Glanbia Nutritionals are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Target: slimfast

FAQ

What transaction does this page cover?

This page covers Glanbia Nutritionals’s acquisition of 100% of Slimfast, an American company specialised in Nutrition & Dietary Supplements, in 2018. Ownership has since evolved, leading to a subsequent transaction with Heartland Food Products in September 2025 (see the dedicated deal page for details).

How was the acquisition of Slimfast by Glanbia Nutritionals valued, and what multiples were paid?

mynth displays the transaction’s enterprise value within the $300–700M band, its EV/EBITDA multiple within the 10x - 18x range, and its EV/revenue multiple within the 1x - 3x range. Exact figures are available to members.

What were Slimfast’s revenue and EBITDA at the time of the deal?

At the time of the transaction, Slimfast generated annual revenue estimated in the $150–250M range and EBITDA in the $10–30M bracket (FY 2017). Detailed financial figures are available to members.

What sources support the information on this transaction?

Data on this transaction was compiled from the official corporate announcement published by the parties, combined with independent reporting from specialized financial and M&A publications.

What is mynth?

mynth is the first free M&A database dedicated to Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.